BioPharma Resources

Drug Trial Radar · NCT07213830

A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies

An Open-label, Phase I/II First in Human, Dose Escalation, Optimisation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Participants With Locally Advanced or Metastatic Solid Tumours Who Have Progressed on or After Immune Checkpoint Inhibitor Therapies

Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 102 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

102

Planned (sponsor's estimate)

Start

Feb 6, 2026

Primary completion

Jul 14, 2032

Study completion Jul 14, 2032

Sponsor

Lead sponsor
IpsenIndustry
Sponsor type
Industry
First posted
Oct 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the appropriate dosage, safety and effectiveness of a new drug, IPN01203, in adults with advanced solid tumours. Advanced solid tumours are cancers that can occur in various organs or tissues and have spread from their original site to nearby tissues or other parts of the body. There will be two parts to this study: * Phase Ia: This part (called dose escalation) will find the dose range that shows activity against the tumour and can be tolerated by participants by testing different increasing doses of IPN01203. * Phase Ib: This part (called dose optimisation) will assess the ability of the drug to prevent, slow down, or stop the growth of tumours and how the body processes and responds to the drug when given in "low dose" or "high dose." It will also further explore the safety and tolerability. An additional part (phase II) may be added to the study based on the results of phase Ia and phase Ib. Each part will consist of the following periods: * A screening period (up to 28 days) to assess whether the participant can take part, requiring at least 1 visit to the study centre. * A treatment period where all eligible participants will receive IPN01203. Requires approximately 15 visits for the first 2 months followed by 3 visits every month from month 3 until unacceptable toxicity, disease progression, death, upon participant's withdrawal of consent, investigator decision, or study termination by the sponsor, whichever occurs first. There will also be one visit at the end of treatment (EoT), 30 days after the last administration of the study intervention or prior to the start of new anticancer treatment, whichever is earlier. Additionally, there will be one visit (the safety follow-up visit) 90 days after the last administration of study intervention or prior to the start of new anticancer treatment, whichever is earlier. In both parts of the study, participants will undergo blood sampling, urine collection, physical examinations and clinical evaluations. They may continue some other medications, but the details need to be recorded. Each participant will be in this study until death or withdrawal from the study. IPN01203 will be provided to participants who tolerate it for as long as their disease does not progress. Participants may withdraw consent to participate at any time.

Conditions

  • Advanced Solid Tumor
  • Metastatic Solid Tumor

Interventions

  • IPN01203Biological

    Study intervention will be provided in a vial.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants with dose limiting toxicity (DLT)Time frame: Within 28 days of first dose
  2. Percentage of participants experiencing treatment emergent adverse events (TEAEs) and treatment emergent serious adverse events (TE-SAEs).Time frame: From the first IPN01203 administration to 90 days after the last dose.
  3. Phase Ib: Objective Response Rate (ORR)Time frame: At end of study (up to approximately 3 years)

Locations

10 sites in 4 countries. Site status is shown where the registry gives one.

  • South Texas Accelerated Research Therapeutics (START) - Midwest

    Grand Rapids, Michigan · Recruiting

  • Sarah Cannon Research Institute - Tennessee Oncology

    Nashville, Tennessee · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • South Texas Accelerated Research Therapeutics (START) - San Antonio

    San Antonio, Texas · Recruiting

  • University Health Network (UHN) - Princess Margaret Cancer Centre

    Toronto, Canada · Recruiting

  • Gustave Roussy Cancer Campus Grand Paris- (Institut de Cancerologie Gustave-Roussy)

    Villejuif, France · Recruiting

  • Hospital Universitario Vall d'Hebron

    Barcelona, Spain · Recruiting

  • NEXT Quiron-Barcelona

    Barcelona, Spain · Recruiting

  • Hospital Fundacion Jimenez Diaz

    Madrid, Spain · Recruiting

  • START Madrid - CIOCC. Grupo Hospital de Madrid (HM) - Centro Integral Oncologico Clara Campal (CIOCC)

    Madrid, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.